Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) snapped a three-day winning streak on Thursday, surging as much as 17.9 percent ...
Recursion (RXRX) lost more than 4% in the early premarket trading on Thursday after a $200M equity offering from the AI-driven drug discovery firm overshadowed a decision by Sanofi (SNY) to select its ...
There has been another major milestone in the field of AI-driven drug discovery (AI drug discovery).I would like to organize ...
15hon MSN
Recursion Pharmaceuticals (RXRX) stock is trending after hours: Here’s what you should know
Recursion Pharmaceuticals Inc. RXRX shares are trending on Friday. Shares of the Utah-based clinical-stage biotechnology ...
Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other ...
Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
I was thinking about a program to solve Sudoku.You fill a 9x9 grid with numbers from 1 to 9. The same number must not be ...
The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for ...
Recursion Pharmaceuticals is maintained at a "Hold" rating, pending further regulatory clarity and late-stage trial ...
Recursion Pharmaceuticals Inc. stocks have been trading up by 14.44 percent following pivotal AI-driven drug discovery ...
Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results